Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AlzChem Group AG (ACT.DE)
Trostberg, DE
AlzChem Group AG operates globally, engaging in the development, production, and distribution of a wide array of chemical products through its subsidiaries. The company's reach extends across Germany, the European Union, the rest of Europe, Asia, the NAFTA region, and other international markets. Its business is organized into three primary divisions: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The diverse product portfolio includes prominent dietary supplements such as Creapure® and Alipure®, along with the creatine-based LIVADUR®. For animal nutrition, AlzChem supplies Creamino®, a guanidinoacetic acid preparation. The pharmaceutical industry benefits from its Bioselect® brand. Industrial applications feature DYHARD® curing agents, acting as accelerators in adhesives, powder coatings, printed circuit boards, and composites, while SILZOT® silicon nitride is vital for ceramics, electronics, and solar technology. The company also manufactures a variety of fine and foundational chemicals, encompassing products derived from calcium carbide, calcium cyanamide (marketed as PERLKA®), hydrogen cyanamide, dicyandiamide, guanidine, guanamines, nitroguanidine, and various aromatic and aliphatic nitriles. Its agricultural offerings include ALZOGUR® germicide for pig pens, Dormex® and Sitofex® plant growth regulators, and BREAK-THRU® plant protection additives. Furthermore, AlzChem provides crucial products for hot metal desulfurization and secondary metallurgy, in addition to technical gases. Beyond its core chemical activities, the group also oversees chemical park operations, offers administrative assistance, and delivers a range of infrastructure services. Established in 1908, AlzChem Group AG maintains its headquarters in Trostberg, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.12% | +2.41% | -4.44% | +14.84% | +25.45% | +5.61% | +38.69% | +728.00% | +567.74% | -27.18% | -98.91% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+1.4% Q1'26: +2.7% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+18.3% ★ Q1'26: +22.9% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+5.2% Q1'26: -3.8% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+14.7% ★ Q1'26: +17.2% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+26.6% ★ Q1'26: +36.2% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%-0.7% ★ Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.42× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 1999 actual |
Dec 2000 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 4 EPS Ana. |
Dec 2027 6 Rev. Ana. 4 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
20.55M
est.
|
16.53M
est.
|
375.22M
est: 376.00M (-0.2%)
|
376.07M
est: 379.00M (-0.8%)
|
379.26M
est: 370.37M (+2.4%)
|
422.29M
est: 411.30M (+2.7%)
|
542.22M
est: 537.53M (+0.9%)
|
540.65M
est: 556.77M (-2.9%)
|
554.23M
est: 560.54M (-1.1%)
|
562.12M
est: 573.78M (-2.0%)
|
603.80M
598.78M – 610.85M
+5.2% YoY
|
701.78M
677.74M – 744.71M
+16.2% YoY
|
796.70M
787.39M – 806.01M
+13.5% YoY
|
762.00M
745.03M – 791.19M
-4.4% YoY
|
| EBITDA |
3.07M
est.
|
-3.11M
est.
|
47.94M
est: -72.02M (+166.6%)
|
45.73M
est: 16.96M (+169.6%)
|
51.39M
est: 45.20M (+13.7%)
|
61.89M
est: 48.23M (+28.3%)
|
68.06M
est: 50.78M (+34.0%)
|
81.75M
est: 148.97M (-45.1%)
|
103.96M
est: 149.54M (-30.5%)
|
109.44M
est: 153.52M (-28.7%)
|
161.55M
160.21M – 163.44M
+5.2% YoY
|
187.77M
181.34M – 199.26M
+16.2% YoY
|
213.17M
210.68M – 215.66M
+13.5% YoY
|
203.88M
199.34M – 211.69M
-4.4% YoY
|
| EBIT |
1.99M
est.
|
-4.99M
est.
|
34.59M
est: -115.38M (+130.0%)
|
30.85M
est: 10.82M (+185.2%)
|
31.03M
est: 31.26M (-0.7%)
|
38.21M
est: 33.35M (+14.6%)
|
44.31M
est: 35.12M (+26.2%)
|
50.80M
est: 127.69M (-60.2%)
|
77.64M
est: 128.18M (-39.4%)
|
82.79M
est: 131.59M (-37.1%)
|
138.48M
137.33M – 140.09M
+5.2% YoY
|
160.95M
155.44M – 170.79M
+16.2% YoY
|
182.72M
180.58M – 184.85M
+13.5% YoY
|
174.76M
170.87M – 181.45M
-4.4% YoY
|
| Net Income |
-494.15M
est.
|
-2.57M
est.
|
22.64M
est: -59.55M (+138.0%)
|
17.98M
est: 6.69M (+168.7%)
|
19.69M
est: 18.37M (+7.2%)
|
27.59M
est: 19.60M (+40.8%)
|
30.05M
est: 20.64M (+45.6%)
|
34.62M
est: 46.34M (-25.3%)
|
54.08M
est: 51.75M (+4.5%)
|
63.46M
est: 62.15M (+2.1%)
|
66.36M
60.64M – 70.57M
+6.8% YoY
|
82.27M
77.46M – 99.82M
+24.0% YoY
|
107.86M
91.23M – 133.66M
+31.1% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
1.43M
est.
|
5.87M
est.
|
37.35M
est: 135.86M (-72.5%)
|
34.11M
est: 84.29M (-59.5%)
|
31.97M
est: 171.88M (-81.4%)
|
29.20M
est: 183.37M (-84.1%)
|
39.62M
est: 193.07M (-79.5%)
|
33.78M
est: 42.21M (-20.0%)
|
31.99M
est: 42.37M (-24.5%)
|
65.55M
est: 43.50M (+50.7%)
|
45.77M
45.39M – 46.31M
+5.2% YoY
|
53.20M
51.38M – 56.45M
+16.2% YoY
|
60.39M
59.69M – 61.10M
+13.5% YoY
|
57.76M
56.48M – 59.98M
-4.4% YoY
|
| EPS |
-48.57
est.
|
-738.96
est.
|
2.23
est: 2.31 (-3.4%)
|
1.77
est: 1.78 (-0.4%)
|
1.94
est: 1.69 (+15.0%)
|
2.72
est: 2.40 (+13.5%)
|
2.97
est: 2.50 (+18.8%)
|
3.40
est: 4.55 (-25.3%)
|
5.31
est: 5.07 (+4.8%)
|
6.28
est: 6.09 (+3.2%)
|
6.55
6.00 – 6.98
+7.5% YoY
|
8.41
7.66 – 9.88
+28.4% YoY
|
10.45
9.03 – 13.23
+24.3% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-15 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andreas Niedermaier | Chief Executive Officer & Chairman of Executive Board | 1M | male |
| Andreas Losle | Chief Financial Officer & Member of Management Board | 655.0K | male |
| Jurgen Sans | COO & Member of Management Board | — | — |
| Martina Spitzer | Chief Sales Officer & Member of Management Board | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACT.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
